7 August 2018
Microsaic Systems plc
("Microsaic", "Microsaic Systems" or the "Company")
Notice of Results
Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, will announce its results for the six months to 30 June 2018 on Monday 3 September 2018.
Enquiries:
|
|
Microsaic Systems plc Glenn Tracey, CEO Bevan Metcalf, FD |
+44 (0) 1483 751 577 |
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson Liz Yong
|
+44 (0)20 7496 3000 |
IFC Advisory Ltd (Financial PR) Graham Herring Heather Armstrong Florence Chandler |
+44 (0)20 3934 6630 |
About Microsaic Systems
Microsaic Systems plc (AIM: MSYS) is a high technology company developing and commercialising chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.
Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.